Compare Ginkgo Bioworks Holdings Inc (DNA) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs UnitedHealth Group Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.17 (market cap $590.53M), while UnitedHealth Group Inc trades at $418 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 659.9× Ginkgo Bioworks Holdings Inc's market cap, and UnitedHealth Group Inc pays a 2.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | UNH | |
|---|---|---|
Market Cap | $590.53M | $389.68B |
Sector | Health | Health |
52-Week High | $16.14 | $431.68 |
52-Week Low | $5.48 | $237.77 |
Enterprise Value | $627.78M | $436.36B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
UnitedHealth Group (UNH) trades at $429.09, up 1.05% on the day, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding expectations, and a dividend of $2.32 payable in June 2026. Revenue growth remains robust, reaching $447.57B in 2025, though net margins have compressed to 2.68%.
Outlook is positive due to aging demographics and tech innovation in healthcare, but risks include regulatory scrutiny and margin pressure. Wall Street's average price target of $438.33 suggests modest upside, supported by 82.69% buy ratings. Investors should weigh solid cash flow generation against legal challenges and rising debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
